SinoMab doses first patient in phase I trial of anti-IL-17RB antibody; LP Pharma, WuXi ATU, Wugen
Elise Mak · 06/16/2022
SinoMab BioScience said on June 15 that the first patient has been dosed in a phase I first-in-human trial of SM17, a humanized, IgG4-k monoclonal antibody targeting IL-17RB, in the U.S. More news from LP Pharma, WuXi ATU, Wugen.
China Resources Biopharma gains Ab Studio's COVID antibody candidate; 3D Medicines, SinoMab, Gloria - News of the day
Elise Mak · 03/16/2022
In a deal without disclosing financial terms, China Resources Biopharma has licensed in U.S. firm Ab Studio's ABS-VIR-001, a trispecific antibody developed as a prophylaxis and therapeutic against SARS-CoV-2 infection. More news from 3D Medicines, SinoMab and Gloria.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback:   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement